Polyrizon Completes Branding Of PL-14 Allergy Blocker As NASARIX, Advancing Commercial Readiness

As part of the branding process, Polyrizon conducted comprehensive trademark screening across the U.S. and European markets

Raanana, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) --  Polyrizon Ltd. Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has completed the branding process for its PL-14 allergy blocker, which will be marketed under the brand name NASARIX™.

NASARIX™ is based on Polyrizon's proprietary Capture and Contain™ (C&C) hydrogel technology, an innovative intranasal spray formulation designed to create a protective physical barrier against allergens and viruses. Establishing the NASARIX™ brand represents an important milestone in Polyrizon's pathway toward future commercialization and supports the Company's ability to communicate the product's differentiated benefits clearly and effectively to patients, healthcare professionals, and commercial partners.

As part of the branding process, Polyrizon conducted comprehensive trademark screening and linguistic evaluations across the U.S. and European markets to support brand viability and alignment with regulatory and market requirements.

Tomer Izraeli, CEO of Polyrizon, commented, "Selecting NASARIX™ as the brand name for PL-14 allergy blocker reflects our commitment to commercial readiness and our focus on building a strong and recognizable identity in the allergy and respiratory health markets. This is a key step as we advance toward upcoming clinical and regulatory milestones."

Polyrizon expects NASARIX™ to be introduced in alignment with its ongoing clinical progress and regulatory pathway.